Acknowledgement
The research resources (tumor tissues from patients with ovarian cancer) were provided by Korea Gynecologic Cancer Bank (KGCB) of the Infrastructure Project for Basic Science of the Ministry of Education, Science, and Technology (MEST), Korea. This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2018R1D1A1B070 43451, NRF-2022R1I1A1A01068767, NRF- 2020R1I1A3073845), and the Korean government (MSIT) (NRF-2020R1A5A2019210). The present study was also supported by RP-Grant 2021 of Ewha Womans University.
References
- Yang L, Zhao H, Yin X et al (2020) Exploring cisplatin resistance in ovarian cancer through integrated bioinformatics approach and overcoming chemoresistance with sanguinarine. Am J Transl Res 12, 923
- Agarwal R and Kaye SB (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3, 502-516 https://doi.org/10.1038/nrc1123
- Makovec T (2019) Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiol Oncol 53, 148-158 https://doi.org/10.2478/raon-2019-0018
- Tapia G and Diaz-Padilla I (2013) Molecular mechanisms of platinum resistance in ovarian cancer; in Ovarian cancer-a clinical and translational update. Diaz-Padilla I (eds.), IntechOpen, UK
- Chang X, Moni tto CL, Demokan S et al (2010) Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer Res 70, 2870-2879 https://doi.org/10.1158/0008-5472.CAN-09-3427
- Bai P (2015) Biology of poly (ADP-ribose) polymerases: the factotums of cell maintenance. Mol Cell 58, 947-958 https://doi.org/10.1016/j.molcel.2015.01.034
- Gibson BA and Kraus WL (2012) New insights into the molecular and cellular functions of poly (ADP-ribose) and PARPs. Nat Rev Mol Cell Biol 13, 411-424 https://doi.org/10.1038/nrm3376
- Caldecott KW, Aoufouchi S, Johnson P and Shall S (1996) XRCC1 polypeptide interacts with DNA polymerase β and possibly poly (ADP-ribose) polymerase, and DNA ligase III is a novel molecular 'nick-sensor' in vitro. Nucleic Acids Res 24, 4387-4394 https://doi.org/10.1093/nar/24.22.4387
- Flohr C, Burkle A, Radicella JP and Epe B (2003) Poly (ADP-ribosyl) ation accelerates DNA repair in a pathway dependent on Cockayne syndrome B protein. Nucleic Acids Res 31, 5332-5337 https://doi.org/10.1093/nar/gkg715
- Mangerich A and Burkle A (2011) How to kill tumor cells with inhibitors of poly (ADP-ribosyl) ation. Int J Cancer 128, 251-265 https://doi.org/10.1002/ijc.25683
- unlu A and Dinc B (2020) Investigation of the three-dimensional structure and interaction mechanism of poly (ADP-ribose) polymerase 4. Biotechnol Biotec Eq 34, 191-202 https://doi.org/10.1080/13102818.2020.1726208
- Siva AC, Raval-Fernandes S, Stephen AG et al (2001) Upregulation of vaults may be necessary but not sufficient for multidrug resistance. Int J Cancer 92, 195-202 https://doi.org/10.1002/1097-0215(200102)9999:9999<::AID-IJC1168>3.0.CO;2-7
- Berger W, Spiegl-Kreinecker S, Buchroithner J et al (2001) Overexpression of the human major vault protein in astrocytic brain tumor cells. Int J Cancer 94, 377-382 https://doi.org/10.1002/ijc.1486
- Ha YN, Sung HY, Yang SD, Chae YJ, Ju W and Ahn JH (2018) Epigenetic modification of α-N-acetylgalactosaminidase enhances cisplatin resistance in ovarian cancer. Korean J Physiol Pharmacol 22, 43-51 https://doi.org/10.4196/kjpp.2018.22.1.43
- Mora Y, Reyes ME, Zanella L et al (2021) Resistance to platinum-based cancer drugs: a special focus on epigenetic mechanisms. Pharmacogenomics 22, 777-790 https://doi.org/10.2217/pgs-2021-0020
- van Zon A, Mossink M, Scheper R, Sonneveld P and Wiemer E (2003) The vault complex. Cell Mol Life Sci 60, 1828-1837 https://doi.org/10.1007/s00018-003-3030-y
- Raval-Fernandes S, Kickhoefer VA, Kitchen C and Rome LH (2005) Increased susceptibility of vault poly (ADP-ribose) polymerase-deficient mice to carcinogen-induced tumorigenesis. Cancer Res 65, 8846-8852 https://doi.org/10.1158/0008-5472.CAN-05-0770
- Szaflarski W, Sujka-Kordowska P, Pula B et al (2013) Expression profiles of vault components MVP, TEP1 and vPARP and their correlation to other multidrug resistance proteins in ovarian cancer. Int J Oncol 43, 513-520 https://doi.org/10.3892/ijo.2013.1975
- Wu H, Li Y, Hou Q et al (2019) Single‑cell intratumoral stemness analysis reveals the involvement of cell cycle and DNA damage repair in two different types of esophageal cancer. Oncol Rep 41, 3201-3208
- Kim NH, Sung HY, Choi EN et al (2014) Aberrant DNA methylation in the IFITM1 promoter enhances the metastatic phenotype in an intraperitoneal xenograft model of human ovarian cancer. Oncol Rep 31, 2139-2146 https://doi.org/10.3892/or.2014.3110